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Abstract
Research suggests a two factor structure for negative symptoms in patients with psychotic
disorders: social amotivation (SA) and expressive deficits (ED). Applying this two-factor struc-
ture in clinical settingsmay provide valuable information with regard to outcomes and to target
treatments. We aimed to investigate 1) whether the factor structure is also supported in chron-
ically ill patients with a psychotic disorder and 2) what the relationship is between these fac-
tors and functioning (overall functioning and living situation), depressive symptoms and
quality of life. 1157 Patients with a psychotic disorder and a duration of illness of 5 years or
more were included in the analysis (data selected from the Pharmacotherapy Monitoring Out-
come Survey; PHAMOUS). A confirmatory factor analysis was performed using items of the
Positive and Negative Syndrome Scale that were previously identified to reflect negative
symptoms (N1-4, N6, G5, G7, G13, G16). Subsequently, regression analysis was performed
on outcomes. The results confirmed the distinction between SA (N2, N4, G16) and ED (N1,
N3, N6, G5, G7, G13) in chronically ill patients. Both factors were related to worse overall
functioning as measured with the Health of the Nation Outcome Scales, ED was uniquely
associated with residential living status. Higher scores for SA were associated with more
depressive symptoms and worse quality of life. Thus, SA is most strongly related to level of
social-emotional functioning, while ED are more related to living situation and thereby are
indicative of level of everyday functioning. This subdivision may be useful for research pur-
poses and be a valuable additional tool in clinical practice and treatment development.
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Introduction
Negative symptoms, such as flattened affect, social withdrawal, apathy and avolition, are core
symptoms of psychotic disorders, most notably schizophrenia. At least half of the patients with
schizophrenia suffers from negative symptoms [1], which are often already present in the pro-
dromal phase [2] and are relatively stable across the course of illness [3]. Negative symptoms
have an invalidating impact on patients’ functioning [4–6] and are associated with lower qual-
ity of life [7]. Despite the increased focus on negative symptoms as a subject of research, there
is still a paucity of (psychosocial) interventions effective in reducing them. Many patients are
left with negative symptoms after their positive symptoms have been partially or completely
managed by antipsychotic medication [8]. The lack of substantial improvement in everyday
functioning after antipsychotic treatment may therefore be impeded by enduring negative
symptoms [9].
An accumulating body of research suggests that negative symptoms are multidimensional
[10]. Factor analytic studies across different instruments consistently cause two factors to
emerge, namely social amotivation (SA) and expressive deficits (ED) [11–14]. The SA subdo-
main encompasses social and emotional withdrawal and speaks to involvement with the envi-
ronment [15]. It refects a reduction of interest in social interactions and life events, and a
reduction of self-initiated or maintained behaviors with regard to social events. SA has been
linked to deficits in anticipatory pleasure (i.e. failure to signal the salience of positive events),
thereby losing the drive to engage in (social) situations and activities [15–17]. Thus, SA can be
interpreted as a ‘loss of interest’ [13]. The ED subdomain involves directly observable compo-
nents such as diminished facial expression, poverty of speech and blunted affect [10,15]. ED is
a reduction of verbal and non-verbal emotional responsiveness, reflected by a reduction of
communicative expression. ED has been associated with impaired neurocognition [11,15,18]
and may reflect a ‘loss of initiative’ [13].
Both factors seem to affect functional and psychosocial outcomes differently [10,19–21].
This has important implications, because many (treatment) studies use total negative symp-
toms scores, which could average out relationships that are mainly driven by one of the subdo-
mains. That is, when subjects demonstrate different scores on each subdomain (high on SA
and low on ED or vice versa), their total of negative symptoms may be similar, while their rela-
tionship with outcomes could be different as this may be driven by one factor. Therefore, a dis-
tinction in subdomains, and more importantly the understanding of possible differential
correlates of these factors, could be of importance for clinical diagnosis, therapeutic decision-
making and research on treatment development [10,11]. Literature suggests that SA is most
strongly associated with functional outcomes such as employment, number of hospitalizations,
instrumental role performance and family functioning [10,14,22,23] and that males may score
higher on SA than ED [14]. However, the role of ED is less clear. Components of ED such as
blunted or flat affect have been associated with poor social functioning and quality of life as
well [24,25], but ED shows weaker associations with outcomes than SA [14] or has no addi-
tional predictive value after controlling for SA [16]. Therefore, SA is often seen as the key con-
tributor to the relationship between negative symptoms and functional outcomes [20]. The
majority of studies investigating the correlates of both domains have focused on functional out-
comes and less on other aspects, such as depressive symptoms, which are common in psychotic
disorder [26], and quality life. Investigating whether the subdomains differentially relate to
quality of life, can guide treatment strategies to more specific targets. For depressive symptoms,
a differential relationship of the subdomains could clarify the inconsistencies with regard to the
association between global negative symptoms and depressive symptoms in the literature.
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However, correlational analysis in one study showed no relationship of either factor with
depressive symptoms, but did show an association between SA and quality of life [13].
The two factors have been mostly established in samples of patients with recent onset psy-
chosis [10,11,13], but one study established the factor structure in patients with chronic psy-
chosis and a longer duration of illness [22]. As a consequence, little is known about this factor
structure in patients with a psychotic disorder with a longer duration of illness. Considering
the paucity of studies investigating the subdomains in chronic populations, replication of the
factor structure in this population is needed. And, if the factor structure is replicated, the rela-
tionship between these factors and functional outcomes and psychosocial well-being should be
examined. Therefore, we aimed to investigate 1) whether the factor structure of negative symp-
toms can be replicated in chronically ill patients with a psychotic disorder and 2) the relation-
ship between these factors and functioning (overall functioning and living situation),
depressive symptoms, and quality of life.
Methods
Participants
Data were selected from the Pharmacotherapy Monitoring Outcome Survey (PHAMOUS).
PHAMOUS is an annual screening of mental and physical health of patients using antipsychot-
ics and receiving mental health care in the North of the Netherlands. We included all patients
between 2011 and 2013, diagnosed with a psychotic disorder, with a duration of illness of more
than 5 years and of whom the Positive and Negative Syndrome Scale (PANSS) items N1-N4,
N6, G7, G13 and G16 were available (items previously identified [13]). When multiple screen-
ings were available of the same patient, the most recent record was selected unless an older
record was more complete. Data were collected in accordance with the latest version of the
Declaration of Helsinki. Data were collected for diagnostic purposes, no interventions outside
standard care were performed. The procedures were in accordance with local and international
rules, as confirmed by the local ethical committee of the University Medical Center of Gro-
ningen, who stated that use of anonymized data from the PHAMOUS protocol for research
purposes does not fall under the scope of the Medical Research Involving Human Subjects Act
and therefore does not need to undergo a prior review by the medical ethical committee.
Assessment measures
The interviews and clinician-rated scales used in this study were assessed and rated by a trained
research nurse, each patient was rated by one nurse.
Functional outcome. Functional outcome was measured with the Health of the Nation
Outcome Scales (HoNOS) [27]. The items of this clinician-rated instrument were scored on a
five point scale ranging from ‘no problem’ to ‘severe to very severe problem’. The HoNOS con-
sist of 4 subscales: behavioral problems, impairment, symptomatic and social problems. The
HoNOS has shown moderately high internal consistency and moderate interrater reliability
[27].
Furthermore, living situation (living in the community versus residential living) was used as
a second measure of functional outcome. Patients who were living on their own, with family,
friends or other housemates were characterized as ‘living in the community’, whereas patients
who were living in sheltered or clinical care facilities fell into the ‘residential living’ category.
Symptom assessment. Symptomatology was measured with the Positive And Negative
Syndrome Scale (PANSS), a commonly used semi-structured interview including three sub-
scales, namely positive symptoms, negative symptoms and general pathology [28], on a seven
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point scale ranging from ranging from ‘absent’ to ‘severe’. The PANSS has shown high internal
consistency and good construct validity [28].
Depressive symptoms were measured with the Calgary Depression Scale for Schizophrenia
(CDSS) [29], a structured interview with nine items on a four point scale, ranging from ‘absent’
to ‘severe’. Depression as measured with the CDSS can predict outcomes differentially from
negative symptoms.
Quality of Life. Quality of life was measured using the Manchester Short Assessment of
Quality of Life (MANSA). The MANSA is a self-report questionnaire and addresses patients’
satisfaction within several psychosocial domains, including satisfaction with life as a whole, job
(or sheltered employment), training/education, or unemployment/retirement), financial situa-
tion, number and quality of friendships, leisure activities, accommodation, personal safety,
people that the patient lives with (or living alone), sex life, relationship with family, physical
health, and mental health [30]. The twelve items that are rated on a seven point scale (‘could
not be worse’ to ‘could not be better’) were used for analysis (the other four items are dichoto-
mous (yes/no) and were excluded for methodological reasons). The MANSA has good con-
struct validity and internal consistency [30].
Statistical analysis
Confirmatory factor analysis. Based on previous work [13], the presupposed two factor
structure of SA and ED was evaluated through confirmatory factor analysis (CFA) with the
computer programMplus version 7 [31]. SA (factor 1) and ED (factor 2) were entered as latent
variables of the nine PANSS items. Because of violation of the multivariate normality assump-
tion, the items were entered according to an ordinal scale using a polychoric correlation matrix.
Furthermore, a robust weighted least squares estimator (WLSMV) was used, as recommended
by the literature [31–34]. To measure the goodness-of-fit (GOF) of the factor structure, the fol-
lowing indices and cut-off criteria were used: the Comparative Fit index (CFI> .95), the Good-
ness-of-Fit index (GFI> .95), the Tucker-Lewis index (TLI>.95), the Root Mean Square Error
of Approximation (RMSEA< 0.06), and the Weighted Root Mean Square of Residuals
(WRMR< 0.90) [31]. Significantly correlated residuals were introduced into the model.
Regression analysis. Hierarchical multiple regression models were used to investigate the
associations between SA and ED scores on the one hand (independent variables) and HoNOS,
CDSS and MANSA total scores and HoNOS subscale scores on the other hand (dependent var-
iables), while controlling for positive symptoms (total score of PANSS positive symptoms sub-
scale), age, gender and antipsychotic medication (expressed in chlorpromazine equivalents
[35]). SA (total score of PANSS items N2, N4, G16) and ED (total score of PANSS items N1,
N3, N6, G5, G7 and G13) were entered in the first block, positive symptoms, age, gender, and
antipsychotic medication were entered in the second block. A logistic regression model was
used to examine the relationship between the negative symptom factors (independent vari-
ables) and living situation (dependent variable; 0 = non-residential, 1 = residential) controlling
for the same confounders. All statistical analyses were performed with IBM SPSS Statistics ver-
sion 22 (IBM Corp, Armonk, NY).
Results
Patient characteristics
In total, 1157 patients fulfilled the inclusion criteria. Baseline demographic and clinical charac-
teristics are presented in Table 1. Patients were mostly male with a mean age of 45 years and
they had been ill for 18,5 years on average (time since first psychotic episode). The majority of
the patients were diagnosed with schizophrenia.
Differential Relationships of Negative Symptom Subdomains
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Table 1. Baseline clinical and demographic characteristics (N = 1157).
Total sample Non-residential Residential
Mean ± SD, N (%) or
median [25th; 75th
percentile] (n = 1157)
Range Mean ± SD, N (%) or
median [25th; 75th
percentile] (n = 693a)
Range Mean ± SD, N (%) or
median [25th; 75th




Age 44.3 ± 10.8 19–72 43.6 ± 10.5 19–71 46.0 ± 11.2 21–72 < .001
Duration of illness 18.5 ± 9.7 5–55 17.21 ± 8.9 5–55 21.1 ± 10.7 5–54 < .001




474 (41.0) 474 (68.4) -
Independent with
partner
122 (10.5) 122 (17.6) -
With family/others 97 (8.4) 97 (14.0) -
Sheltered living/
social pension
247 (21.3) - 247 (63.3)
Long-stay clinical
facilities
143 (12.4) - 143 (36.7)
Other/unknown 74 (6.4) - -
Diagnosis
Schizophrenia 848 (73.3) 466 (67.2) 322 (82.6) < .001
Schizoaffective
disorder
180 (15.6) 127 (18.3) 44 (11.3) .002
Psychotic disorder
NOS
98 (8.5) 78 (11.3) 16 (4.1) < .001
Schizophreniform
disorder
18 (1.6) 15 (2.2) 3 (0.8) .135
Delusional disorder 13 (1.1) 7 (1.0) 5 (1.3) .765
Psychiatric
comorbidityb
340 (29.4) 170 (24.5) 145 (62.8) < .001
Substance abuse 137 (11.8) 71 (10.2) 57 (14.6) .081
Developmental
disorder
24 (2.1) 13 (1.9) 10 (2.6) .537
Anxiety disorder 25 (2.2) 17 (2.5) 6 (1.5) .411
Somatoform disorder 1 (0.1) - 1 (0.3) .360
Personality disorder 155 (13.4) 78 (11.3) 64 (16.4) .025




None 76 (6.6) 55 (8.0) 20 (5.1) .082
Clozapine 335 (29.0) 140 (20.2) 177 (45.4) < .001
Risperidone 194 (16.8) 76 (11.0) 37 (9.5) .542
Olanzapine 207 (17.9) 120 (17.3) 68 (17.4) .934
Aripiprazol 157 (13.6) 105 (15.2) 41 (10.5) .036
Quetiapine 107 (9.2) 73 (10.5) 27 (6.9) .039
Haloperidol 75 (6.5) 32 (4.6) 17 (4.4) .880
Otherc 308 (26,6) 195 (28.1) 166 (42.6) < .001
Nr of antipsychotics 1.2 ± 0.6 0–4 1,1 ± 0.5 0–4 1.4 ± 0.7 0–4 < .001
CPZ equivalent
(mg/d)d
350 [150; 600] 0–3037.5 300 [115; 525] 0–1800 480 [225; 750] 0–3037.5 < .001
(Continued)
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Factor analysis
In Table 2 we present the results of standardized factor loadings with significant correlated
residuals. The goodness of fit indices for the CFA are good according the criteria given in the
literature [36]. The RMSEA is 0.06 (CI 90%: 0.05–0.07), the WRMR is 0.86 [31], CFI is 0.99
and TLI is 0.98. All factor loadings are above 0.5.
Hierarchical regression
Data distributions were examined for linearity and normality. CDSS scores and HoNOS behav-
ioral problems scores were positively skewed. The distribution was improved after applying
square root transformations. Furthermore, there was no evidence for multicollinearity in the
regression models. Hierarchical regression analyses were performed to investigate the relation-
ship between both SA and ED and the outcome measures.
The analyses revealed that higher SA was significantly related to worse overall functioning
(HoNOS total score), more depressive symptoms (CDSS) and worse quality of life (MANSA)
(results of the final models are shown in Table 3). For the HoNOS subscales, higher SA was
associated with symptomatic problems and social problems (see S1 Table). The observed asso-
ciations remained significant after controlling for positive symptoms, age, gender and antipsy-
chotic medication.
With regard to ED, higher scores were related to significantly worse overall functioning
(HoNOS total score) and depressive symptoms. A positive relationship between ED and quality
Table 1. (Continued)
Total sample Non-residential Residential
Mean ± SD, N (%) or
median [25th; 75th
percentile] (n = 1157)
Range Mean ± SD, N (%) or
median [25th; 75th
percentile] (n = 693a)
Range Mean ± SD, N (%) or
median [25th; 75th





2.4 ± 2.7 0–16 1.8 ± 2.1 0–15 3.7 ± 3.1 0–16 < .001
Outcomes
PANSS total 51.9 ± 15.7 30–132 48.2 ± 13.7 30–100 57.3 ± 16.7 30–132 < .001
PANSS positive 12.1 ± 4.8 7–38 11.4 ± 4.4 7–31 13.0 ± 5.3 7–38 < .001
PANSS negative 13.8 ± 6.0 7–42 12.4 ± 5.1 7–32 16.1 ± 6.5 7–42 < .001
PANSS general 25.9 ± 7.9 16–69 24.4 ± 6.8 16–50 28.1 ± 8.6 16–69 < .001
PANSS social
amotivation
5 [3;8] 3–20 5 [3; 7] 3–17 6 [4; 9] 3–16 < .001
PANSS expressive
deﬁcits
9 [7;13] 6–34 8 [6;12] 6–27 11 [8; 15] 6–34 < .001
HoNOS total 9.5 ± 5.7 0–37 8.1 ± 5.1 0–26 11.7 ± 5.1 0–37 < .001
CDSS total 2.5 ± 3.1 0–17 2.5 ± 3.2 0–17 2.3 ± 2.7 0–12 .384
MANSA total 59.2 ± 12.1 14–84 59.6 ± 11.4 26–84 59.0 ± 13.2 14–84 .457
Abbreviations: CPZ: chlorpromazine; PANSS: Positive and Negative Syndrome Scale; HoNOS: Health of the Nation Outcome Scales (subtotal of items 4,
7, 8, 9 and 10); CDSS: Calgary Depression Scale for Schizophrenia; MANSA: Manchester Short Assessment of Quality of Life.
a Of 74 patients the living situation was unknown
b Nr of patients with one or more comorbid psychiatric disorder, most comorbid disorders were personality disorders (19.0%) and substance abuse
disorders (16.8%).
c Other medication included: zuclopentixol (22.7%), paliperidon (13.7%), ﬂupentixol (9.3), pimozide (7.6%), miscellaneous (46,7%).
d Chlorpromazine equivalents of antipsychotic dosage were calculated based on Gardner and colleagues [35].
doi:10.1371/journal.pone.0149785.t001
Differential Relationships of Negative Symptom Subdomains
PLOS ONE | DOI:10.1371/journal.pone.0149785 February 19, 2016 6 / 13
of life was found, indicating that higher ED was associated with higher quality of life. Higher
ED scores were associated with higher scores on the HoNOS impairment subscale (cognitive
and psychical or disability problems), the behavioral problems subscale and the social problems
subscale. Logistic regression analyses revealed that ED was associated with residential living
status (living in sheltered or clinical care facilities), which remained significant after controlling
for confounders (Table 4).
Discussion
In this study we established that the negative symptoms factor structure consisting of social
amotivation (SA) and expressive deficits (ED) also holds in a chronic population with psy-
chotic disorders. It thereby extends previous reports demonstrating two separate factors of neg-
ative symptoms in patients in the early phase of their psychotic illness [13] and factor analytic
Table 2. Results of confirmatory factor analysis: univariate proportions of the items and factor loadings of items N1-N4, N6, G5, G7, G13 and G16
of the PANSS (N = 1157).
Univariate proportions of the items
PANSS item* Category 1 Category 2 Category 3 Category 4 Category 5 Category 6 Category 7 Factor loading
Factor 1 (social amotivation)
N2 Emotional withdrawal 0.408 0.274 0.167 0.114 0.027 0.01 0.001 0.938
N4 Passive/apathetic 0.367 0.243 0.208 0.088 0.072 0.02 0.001 0.872
G16 Active social avoidance 0.593 0.207 0.135 0.035 0.024 0.004 0.002 0.674
Factor 2 (expressive deﬁcits)
N1 Flat affect 0.361 0.22 0.199 0.118 0.095 0.003 0.005 0.821
N3 Poor rapport 0.58 0.171 0.183 0.041 0.016 0.006 0.003 0.847
N6 Lack of spontaneity 0.596 0.145 0.161 0.064 0.022 0.01 0.002 0.793
G5 Mannerisms and posturing 0.707 0.144 0.124 0.014 0.004 0.004 0.003 0.504
G7 Motor retardation 0.649 0.152 0.147 0.046 0.004 0.002 0 0.651
G13 Avolition 0.709 0.128 0.114 0.04 0.009 0.001 0 0.585
Abbreviations: PANSS: Positive and Negative Syndrome Scale
* signiﬁcant correlated residuals are (N1 with N2,N6,G7,G13,G16); (N2 with N4); (N6 with N3,G7); (G5 with G7,G16).
doi:10.1371/journal.pone.0149785.t002
Table 3. Hierarchical multiple regression models for overall functioning, quality of life and depressive symptoms.
HoNOS (N = 715) a CDSS (N = 588) b MANSA (N = 777)c
Step Variable added β t p Adj. R2 β t P Adj. R2 β t P Adj. R2
1 Social amotivation .173 3.925 < .001 .158 .227 4.419 < .001 .066 -.184 -3.908 < .001 .032
Expressive deﬁcits .127 2.914 .004 .037 .733 .464 .096 2.047 .041
2 PANSS positive .341 9.911 < .001 .272 .150 3.624 < .001 .102 -.200 -5.416 < .001 .086
CPZ eq .065 1.936 .053 -.048 -1.177 .240 .031 .866 .387
Age .029 .906 .365 -.079 -1.964 .050 .137 3.886 < .001
Gender .023 .699 .485 -.130 -3.236 .001 -.066 -1.855 .064
Abbreviations: PANSS: Positive and Negative Syndrome Scale; CPZ: chlorpromazine; HoNOS: Health of the Nation Outcome Scales (subtotal of items 4,
7, 8, 9 and 10); CDSS: Calgary Depression Scale for Schizophrenia; MANSA: Manchester Short Assessment of Quality of Life.
a Overall adjusted model R2 = .278, F(6.708) = 45.357, p < .001
b Overall adjusted model R2 = .111, F(6.576) = 12.035, p < .001
c Overall adjusted model R2 = .093, F(6.751) = 12.858, p < .001.
doi:10.1371/journal.pone.0149785.t003
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studies using the Scale for Assessment of Negative Symptoms (SANS) [37] or the Schedule for
Deficit Syndrome (SDS) [38] (see for an overview [39]). Furthermore, the SA factor was associ-
ated with more depressive symptoms and worse quality of life, while the ED factor was most
importantly related to residential living status. These relationships were not affected by positive
symptoms, age, gender or antipsychotic dosage.
The replication of the dimensional structure of negative symptoms provides good support
for the subdomains across the course of illness, which was not yet firmly established in chronic
samples. Furthermore, the dimensional structure of the PANSS is an important addition to the
factor analytic studies using the SANS and SDS, because the PANSS is widely used in clinical
trials as well as in clinical practice and recognized as an appropriate tool for assessing negative
symptoms [40]. As such, subdomains SA and ED can be used to assess differences in treatment
response and eventually guide clinical practice in choosing a treatment strategy. There are a
few notable differences in the PANSS factor analytic results compared to other instruments
that should not go without mention. The main difference between the SANS studies and our
results, is that PANSS avolition item (G13) loads on ED, while the SANS avolition items load
on SA. PANSS ratings for avolition are merely based on observed behavior and could therefore
be rated as a disturbance in willful initiation of behavior or facial expression, whereas the
SANS avolition items may be rated more of a social motivational deficit [13]. Furthermore, the
avolition item of the PANSS (G13) and the mannerisms and posing item (G5), which also
loads on the ED factor in our study, have previously been reported as part of the disorganized
factor of the PANSS. These items were nevertheless included in our analysis, because previous
work showed that the factor loadings warranted inclusion in ED and that removal of these
items did not improve the model fit [13]. The current factor loadings of G5 and G13 were com-
parable to this previous study.
The value of the distinction in subdomains is its relationship with functional and clinical
outcomes [41]. Most importantly we found that higher ED was related to residential living (i.e.
living in a sheltered or clinical care facility), while SA was related to more depressive symptoms
and lower quality of life. Residential patients generally have a more severe course of illness and
the poorest outcomes. This suggests that ED is more strongly associated with a more severe
course of illness and poorer functional outcomes, contradicting evidence for SA as the key pre-
dictor of functioning [14,22]. A possible explanation for the relationship with residential living
is that patients with ED seem more ‘ill’. That is, family, friends or health care workers may
more often interpret SA as for example demoralization, indifference or laziness; extremes of
‘normal’ behavior. ED on the other hand, is more difficult to place within the frames of normal
behavior and can seem more deviant and therefore lead to seeking help, for example in the
Table 4. Logistic regression model for living situation: admission to sheltered or clinical facility (N = 1018).
Stepa Variables B OR 95% C.I. for OR
1 Social amotivation -.053 .948 .893–1.007
Expressive deﬁcits .118 1.126 1.080–1.174*
PANSS positive .049 1.050 1.018–1.083*
CPZ equivalent .001 1.001 1.001–1.002*
Age .019 1.019 1.006–1.033*
Gender -.531 .588 .428–.808*
Abbreviations: PANSS: Positive and Negative Syndrome Scale; CPZ: chlorpromazine; OR = Odds ratio; C.I. = conﬁdence interval
a reference category: non-residential living
* p < .001.
doi:10.1371/journal.pone.0149785.t004
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form of admission to a residential care facility. Indeed, ED has been linked to neurocognitive
deficits before [11,13,15,18] and was related to the impairment subscale of the HoNOS in this
study (measuring cognition and disability) confirming higher disability and higher need for
intensive (residential) care. Interestingly, these patients do not report lower quality of life than
less disabled patients (given that higher ED was related to better quality of life; see also De
Heer-Wunderink and colleagues [42]). The experience of a good ‘person-environment fit’ by
the residential group may in part explain these findings.
Previous findings on the relationship between negative symptoms and depression have been
inconsistent (i.e. some studies have reported an association [43–45], while others have not [46–
48]). Our findings indeed suggest a relationship between depressive symptoms and negative
symptoms. However, this relationship seems to be limited to SA. This suggests that the inconsis-
tency in the relationship between depression and negative symptoms may (in part) be explained
by the subdomain structure of negative symptoms. That is, when subjects demonstrate different
scores on each subdomain (high on SA and low on ED or vice versa), their total of negative symp-
toms may be similar, while their relationship with depression is different as this is driven by SA.
Quality of life was significantly associated with SA. This is in line with previous work [13].
In addition, we found a relationship between SA and the subscale social problems of the
HoNOS (S1 Table). Since quality of life has also been associated with social functioning
[49,50], this leads us to suggest that the relationship between SA and quality of life is of an indi-
rect nature. That is, SA causes problems with social functioning, which in turn has an effect
upon the subjective quality of life. A mediation analysis demonstrated that the relationship
between SA and quality of life was indeed influenced by social problems (partial mediation)
(S1 Fig). However, since we did not explicitly state any hypothesis with regard to this relation-
ship, this interpretation should be treated with caution. Higher ED was associated with better
quality of life. The direction of this association is surprising and the strength of the association
increased upon including positive symptoms in the regression model. This suggests that other
factors influence this relationship, which makes this result difficult to interpret with the current
data and deserves further investigation.
Taken together, our results seem to indicate that both factors differentially relate to distinct
aspects of functioning. SA seems to be most strongly related to social-emotional aspects of
functioning, reflected in associations with depressive and psychological symptoms (HoNOS
subscale) and quality of life. ED on the other hand, seems to be more strongly related to aspects
of everyday functioning and behavioral problems, as reflected by its associations with living sit-
uation, cognitive and disability problems (HoNOS impairment subscale) and the behavioral
problems subscale of the HoNOS.
Keeping in mind that replication is needed in both chronic and other samples, some clinical
implications of these findings could be cautiously suggested. Considering that SA has been
linked to deficits in anticipatory pleasure [15–17], the individually oriented Cognitive Behav-
ioral Therapy (CBT) model constructed by Staring and colleagues [51] that specifically aims at
reducing negative symptoms by targeting dysfunctional beliefs including experiencing plea-
sure, could be particularly suited to target SA. For ED, the loss of initiative factor, personalized
rehabilitation approaches aimed at examining each patient’s wishes and strengths, and accept-
ing and working around the impairments, may be most suitable. These could include the reha-
bilitation approach by Anthony and colleagues [52], or compensatory strategies such as
Cognitive Adaptation Training [53] or Cognitive Compensatory Training [54]. Some pharma-
cological treatments have shown to selectively impact SA and ED. For example, add-on mirta-
zapine or selegiline showed a selective effect on SA, while add-on galantamine showed specific
effects on ED, and amisulpride affected both subdomains [21]. However, further research into
the effects of drugs on the specific subdomains is needed.
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Future research should focus on the distinction between social-emotional functioning and
everyday activities to further disentangle the differential clinical correlates of both factors and
to elucidate the inconsistencies in the literature. Longitudinal studies should investigate
whether early interventions are useful in preventing the development of subdomain related
functional problems. Intervention studies that take the subdivision of negative symptoms into
account are still rare. Further, it would be useful to investigate whether the subdomains
retrieved from the PANSS and SANS are interchangeable (which one would expect based on
the high correlation between the PANSS negative subscale and the SANS [55]), in order to
examine whether inconsistencies with regard to the functional correlates can be explained by
the scale that is used. Efforts have been made in developing scales which reliably measure both
subdomains of negative symptoms [56,57].
Strengths of this study are its large sample size and the fact that the data were derived from
a Routine Outcome Monitoring database for which patients were not selected for research pur-
poses and therefore are representative of the real-world population. Another strength of our
study is that we did not only focus on functional outcomes but on depression and subjective
quality of life as well. A limitation is the relatively low negative symptom scores (on average a
rating of ‘minimal’ on each item). The lack of inclusion criteria with regard to negative symp-
tom severity may have biased our results. Future research with patients with more profound
negative symptoms is necessary to further investigate whether the relationships that we found
are also applicable to those with severe negative symptoms. Furthermore, we were not able to
explore proposed underlying mechanisms of SA and ED because cognitive measures and mea-
sures of anticipatory pleasure were not part of the standard PHAMOUS screening. Different
neurobiological correlates have been proposed for lack of interest versus lack of initiative [58],
concepts related to the present two negative factors, which deserve further investigation.
In conclusion, this study replicates the multidimensionality of negative symptoms and
showed unique correlates of these two factors. Our results suggest that SA is predominantly
related to social-emotional aspects of functioning, and that ED is particularly related to aspects
of everyday functioning. Better understanding of the negative symptom subdomains is of value
in developing treatments targeting negative symptoms in schizophrenia, which still represent
an unmet need in this patient population.
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